{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-129351","form_type":"8-K","ticker":"WW","cik":"0000105319","company_name":"WW INTERNATIONAL, INC.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.058202+00:00","generated_at":"2026-06-02T23:49:14.612868+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"WW Q1 2024: Revenue $206.5M, op loss $269.3M on $258M impairment; subscriber flat 4.0M","bullets":["Revenue $206.5M (-14.6% YoY); subscription revenue $204.1M (-3.3%); other revenue $2.5M (-92%).","Operating loss $269.3M from $258M non-cash intangible impairment; adjusted operating loss $5.6M.","Net loss $347.9M ($4.39 EPS) vs $118.7M ($1.68) prior year.","End period subscribers 4.0M flat YoY; clinical subscribers 91K (from zero).","FY2024 guidance: total subscribers 3.8-4.0M, clinical 140-160K; revenue guidance maintained."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-129351","json":"https://secwatch.observer/filing/0001193125-24-129351.json","markdown":"https://secwatch.observer/filing/0001193125-24-129351.md","text":"https://secwatch.observer/filing/0001193125-24-129351.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/105319/000119312524129351/0001193125-24-129351-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/105319/000119312524129351/d787506d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T23:49:14.612868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d52cc792e3fc3895f2a27dcc1b4dcd4a0de751a2","claim":"WW INTERNATIONAL, INC. reported first quarter of fiscal 2024 results: revenue $206.5 million. Guidance reaffirmed.","evidence_excerpt":"WW International, Inc. Announces First Quarter 2024 Results • End of Period Subscribers of 4.0 million, including 91 thousand End of Period Clinical Subscribers • Revenues of $206.5 million • Gross margin of 66.7%; excluding the net impact of restructuring charges related to prior year restructuring plans, adjusted gross margin of 67.9% • Operating Loss of $269.3","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/105319/000119312524129351/0001193125-24-129351-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of fiscal 2024"},{"label":"Revenue","value":"$206.5 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}